Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc. et al

DocketCASE NO LONGER REFERRED to Magistrate Judge Burke for the purpose of exploring ADR. Please see the Court's Standing Order No. 2022-2 dated March 14, 2022. (dlb) (Entered: 04/11/2022)

Docket(#818) Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Joint Status Report - re (38 in 1:18-cv-01040-LPS) Order, (55 in 1:18-cv-01038-LPS) Order,. (Silver, Daniel) (Entered: 04/01/2022)

Docket(#817) FINAL JUDGMENT AND ORDER OF INJUNCTION - re Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. Signed by Judge Kent A. Jordan on 1/21/21. (amf) (Entered: 01/21/2021)

Docket(#816) PROPOSED CONSENT JUDGMENT and Order of Injunction by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 01/19/2021)

Docket(#815) ORDER - In accordance with the Court's December 10, 2020 Order (D.I. #810 ), the Clerk's Office is hereby directed to unseal the Memorandum Opinion of December 10, 2020 (D.I. #809 ). Signed by Judge Kent A. Jordan on 12/16/2020. (amf) (Entered: 12/16/2020)

Docket(#814) Letter to The Honorable Kent A. Jordan from Daniel M. Silver, Esq. regarding Parties' Request to Unseal Memorandum Opinion (D.I. 809) - re #810 Order,. (Silver, Daniel) (Entered: 12/15/2020)

Docket(#813) ORDER - Plaintiff Novartis's Motion to Extinguish Any Claim by Defendant HEC To The Preliminary Injunction Bond (D.I. #785 ) is GRANTED. Signed by Judge Kent A. Jordan on 12/15/2020. (amf) (Entered: 12/15/2020)

Docket(#812) MEMORANDUM OPINION. Signed by Judge Kent A. Jordan on 12/15/2020. (amf) (Entered: 12/15/2020)

Docket(#811) ORDER, denying D.I. #784 Motion for partial Stay of the final judgment; denying as moot D.I. #796 Motion for Leave to File. Signed by Judge Kent A. Jordan on 12/10/2020. (myr) (Entered: 12/10/2020)

Docket(#810) ORDER, re D.I. #809 Memorandum Opinion (UNDER SEAL). Counsel shall provide the Court with proposed redactions to that document on or before the close of business on December 21, 2020. After that time the Court will unseal the Memorandum Opinion, setting forth the rulings, with any redactions deemed appropriate by the Court. Signed by Judge Kent A. Jordan on 12/10/2020. (myr) (Entered: 12/10/2020)

DocketSummons Reissued with Magistrate Consent Notice attached as to Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc. (nmg) (Entered: 07/19/2018)

DocketSummons Reissued with Magistrate Consent Notice attached as to Accord Healthcare Inc., HEC Pharm Group, Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Par Pharmaceutical Inc., Zydus Pharmaceuticals (USA) Inc.. (nmg) (Entered: 07/19/2018)

DocketCase Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. Associated Cases: 1:18-cv-01038-LPS, 1:18-cv-01039-LPS, 1:18-cv-01040-LPS, 1:18-cv-01043-LPS (rjb) (Entered: 07/18/2018)

DocketSummons Issued with Magistrate Consent Notice attached as to Accord Healthcare Inc. on 7/18/2018; Alkem Laboratories Ltd. on 7/18/2018; Aurobindo Pharma Limited on 7/18/2018; Aurobindo Pharma USA, Inc. on 7/18/2018; Biocon Limited on 7/18/2018; Biocon Pharma, Inc. on 7/18/2018; Bionpharma Inc. on 7/18/2018; Breckenridge Pharmaceutical, Inc. on 7/18/2018; Cadila Healthcare Limited on 7/18/2018; Dr. Reddys Laboratories, Inc. on 7/18/2018; Dr. Reddys Laboratories, Ltd. on 7/18/2018; Emcure Pharmaceuticals on 7/18/2018; Ezra Ventures, LLC on 7/18/2018; First Time US Generics LLC on 7/18/2018; Glenmark Pharmaceuticals Inc., USA on 7/18/2018; Glenmark Pharmaceuticals Limited on 7/18/2018; HEC Pharm Co., Ltd. on 7/18/2018; HEC Pharm Group on 7/18/2018; HEC Pharm USA Inc. on 7/18/2018; Heritage Pharmaceuticals Inc. on 7/18/2018; Hetero Labs Limited on 7/18/2018; Hetero Labs Limited Unit-V on 7/18/2018; Hetero USA Inc. on 7/18/2018; Intas Pharmaceuticals Limited on 7/18/2018; MSN Laboratories Private Limited on 7/18/2018; MSN Pharmaceuticals Inc. on 7/18/2018; Mylan Pharmaceuticals, Inc. on 7/18/2018; Nostrum Laboratories Inc. on 7/18/2018; Nostrum Pharmaceuticals, LLC on 7/18/2018; Par Pharmaceutical Inc. on 7/18/2018; Prinston Pharmaceutical Inc. on 7/18/2018; S&B Pharma, Inc. on 7/18/2018; Standard Chemical & Pharmaceutical Co., Ltd. on 7/18/2018; Strides Global Pharma Private Limited on 7/18/2018; Strides Pharma, Inc. on 7/18/2018; Torrent Pharma Inc. on 7/18/2018; Torrent Pharmaceuticals Ltd. on 7/18/2018; Zydus Pharmaceuticals (USA) Inc. on 7/18/2018. (sar) (Entered: 07/18/2018)

DocketNo Summons Issued. (nmg) (Entered: 07/16/2018)

Docket(#5) Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (nmg) (Entered: 07/16/2018)

Docket(#4) Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,187,405. (nmg) (Entered: 07/16/2018)

Docket(#3) Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: See Attached. Date of Expiration of Patent: 6/25/2027. (nmg) (Entered: 07/16/2018)

Docket(#2) Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmg) (Entered: 07/16/2018)

Docket(#1) COMPLAINT for PATENT INFRINGEMENT filed against Accord Healthcare Inc., Alkem Laboratories Ltd., Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Biocon Limited, Biocon Pharma, Inc., Bionpharma Inc., Breckenridge Pharmaceutical, Inc., Cadila Healthcare Limited, Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Emcure Pharmaceuticals, Ezra Ventures, LLC, First Time US Generics LLC, Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited, HEC Pharm Co., Ltd., HEC Pharm Group, HEC Pharm USA Inc., Heritage Pharmaceuticals Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Intas Pharmaceuticals Limited, MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., Mylan Pharmaceuticals, Inc., Nostrum Laboratories Inc., Nostrum Pharmaceuticals, LLC, Par Pharmaceutical Inc., Prinston Pharmaceutical Inc., S&B Pharma, Inc., Standard Chemical & Pharmaceutical Co., Ltd., Strides Global Pharma Private Limited, Strides Pharma, Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Zydus Pharmaceuticals (USA) Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2420075.) - filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B, #2 Civil Cover Sheet)(nmg) (Entered: 07/16/2018)